Global Liquid Biopsy Market 2018-2022
出 版 商：Technavio
出版日期：2018/07/13
頁 數：119頁
文件格式：PDF
價 格：
USD 2,500 (Single-User License)
USD 3,000 (Multi-User License)
USD 4,000 (Global-User License)
USD 3,000 (Multi-User License)
USD 4,000 (Global-User License)
About Liquid Biopsy
Liquid biopsy is also called fluid biopsy or fluid phase biopsy. It is a simple and non-invasive test to detect genetic changes in the tumor through a simple blood or urine sample. The preference toward liquid biopsy is significantly increasing over traditional tissue biopsy due to its less invasive nature and growing focus on personalized medicine in oncology diagnosis and treatment.
Technavio’s analysts forecast the global liquid biopsy market to grow at a CAGR of 34.25% during the period 2018-2022.
Covered in this report
The report covers the present scenario and the growth prospects of the global liquid biopsy market for 2018-2022. To calculate the market size, the report considers the revenue generated by the use of the liquid biopsy technologies including CTC and ctDNA and exosome and RNA.
The market is divided into the following segments based on geography:
‧ Americas
‧ APAC
‧ EMEA
Technavio's report, Global Liquid Biopsy Market 2018-2022, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.
Key vendors
‧ BIOCEPT
‧ Exosome Diagnostics
‧ F. Hoffmann-La Roche
‧ GUARDANT HEALTH
‧ Myriad Genetics
‧ QIAGEN
Market driver
‧ Growing focus on personalized medicine for cancer care
‧ For a full, detailed list, view our report
Market challenge
‧ Dearth of skilled technicians
‧ For a full, detailed list, view our report
Market trend
‧ Emerging applications of liquid biopsy
‧ For a full, detailed list, view our report
Key questions answered in this report
‧ What will the market size be in 2022 and what will the growth rate be?
‧ What are the key market trends?
‧ What is driving this market?
‧ What are the challenges to market growth?
‧ Who are the key vendors in this market space?
You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.
Liquid biopsy is also called fluid biopsy or fluid phase biopsy. It is a simple and non-invasive test to detect genetic changes in the tumor through a simple blood or urine sample. The preference toward liquid biopsy is significantly increasing over traditional tissue biopsy due to its less invasive nature and growing focus on personalized medicine in oncology diagnosis and treatment.
Technavio’s analysts forecast the global liquid biopsy market to grow at a CAGR of 34.25% during the period 2018-2022.
Covered in this report
The report covers the present scenario and the growth prospects of the global liquid biopsy market for 2018-2022. To calculate the market size, the report considers the revenue generated by the use of the liquid biopsy technologies including CTC and ctDNA and exosome and RNA.
The market is divided into the following segments based on geography:
‧ Americas
‧ APAC
‧ EMEA
Technavio's report, Global Liquid Biopsy Market 2018-2022, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.
Key vendors
‧ BIOCEPT
‧ Exosome Diagnostics
‧ F. Hoffmann-La Roche
‧ GUARDANT HEALTH
‧ Myriad Genetics
‧ QIAGEN
Market driver
‧ Growing focus on personalized medicine for cancer care
‧ For a full, detailed list, view our report
Market challenge
‧ Dearth of skilled technicians
‧ For a full, detailed list, view our report
Market trend
‧ Emerging applications of liquid biopsy
‧ For a full, detailed list, view our report
Key questions answered in this report
‧ What will the market size be in 2022 and what will the growth rate be?
‧ What are the key market trends?
‧ What is driving this market?
‧ What are the challenges to market growth?
‧ Who are the key vendors in this market space?
You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.
PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
PART 03: RESEARCH METHODOLOGY
PART 04: MARKET LANDSCAPE
‧ Market ecosystem
‧ Market characteristics
‧ Market segmentation analysis
PART 05: MARKET SIZING
‧ Market definition
‧ Market sizing 2017
‧ Market size and forecast 2017-2022
PART 06: FIVE FORCES ANALYSIS
‧ Bargaining power of buyers
‧ Bargaining power of suppliers
‧ Threat of new entrants
‧ Threat of substitutes
‧ Threat of rivalry
‧ Market condition
PART 07: MARKET SEGMENTATION BY TECHNOLOGY
‧ Segmentation by technology
‧ Comparison by technology
‧ CTC and ctDNA
‧ Exosome and RNA
‧ Market opportunity by technology
PART 08: CUSTOMER LANDSCAPE
PART 09: REGIONAL LANDSCAPE
‧ Geographical segmentation
‧ Regional comparison
‧ Liquid biopsy market in Americas
‧ Liquid biopsy market in EMEA
‧ Liquid biopsy market in APAC
‧ Market opportunity
PART 10: DECISION FRAMEWORK
PART 11: DRIVERS AND CHALLENGES
‧ Market drivers
‧ Market challenges
PART 12: MARKET TRENDS
‧ Increasing funding/investment for liquid biopsy
‧ Strategic partnerships and M&A
‧ Emerging applications of liquid biopsy
PART 13: VENDOR LANDSCAPE
‧ Overview
‧ Landscape disruption
PART 14: VENDOR ANALYSIS
‧ Vendors covered
‧ Vendor classification
‧ Market positioning of vendors
‧ BIOCEPT
‧ Exosome Diagnostics
‧ F. Hoffmann-La Roche
‧ GUARDANT HEALTH
‧ Myriad Genetics
‧ QIAGEN
PART 15: APPENDIX
‧ List of abbreviations
Exhibit 01: Global IVD market
Exhibit 02: Global IVD market segmentation
Exhibit 03: Market characteristics
Exhibit 04: Market segments
Exhibit 05: Market definition - Inclusions and exclusions checklist
Exhibit 06: Global liquid biopsy market size 2017
Exhibit 07: Validation techniques employed for market sizing 2017
Exhibit 08: Global liquid biopsy market – Market size and forecast 2017-2022 ($ mn)
Exhibit 09: Global liquid biopsy market – Year-over-year growth 2018-2022 (%)
Exhibit 10: Five forces analysis 2017
Exhibit 11: Five forces analysis 2022
Exhibit 12: Bargaining power of buyers
Exhibit 13: Bargaining power of suppliers
Exhibit 14: Threat of new entrants
Exhibit 15: Threat of substitutes
Exhibit 16: Threat of rivalry
Exhibit 17: Market condition - Five forces 2017
Exhibit 18: Global liquid biopsy market by technology – Market share 2017-2022 (%)
Exhibit 19: Global liquid biopsy market – Comparison by technology
Exhibit 20: Global CTC and ctDNA market – Market size and forecast 2017-2022 ($ mn)
Exhibit 21: Global CTC and ctDNA market – Year-over-year growth 2018-2022 (%)
Exhibit 22: Global exosome and RNA market – Market size and forecast 2017-2022 ($ mn)
Exhibit 23: Global exosome and RNA market – Year-over-year growth 2018-2022 (%)
Exhibit 24: Market opportunity by technology
Exhibit 25: Customer landscape
Exhibit 26: Global liquid biopsy market by geography 2017-2022 (%)
Exhibit 27: Regional comparison
Exhibit 28: Liquid biopsy market in Americas – Market size and forecast 2017-2022 ($ mn)
Exhibit 29: Liquid biopsy market in Americas – Year-over-year growth 2018-2022 (%)
Exhibit 30: Top 3 countries in Americas
Exhibit 31: Liquid biopsy market in EMEA – Market size and forecast 2017-2022 ($ mn)
Exhibit 32: Liquid biopsy market in EMEA – Year-over-year growth 2018-2022 (%)
Exhibit 33: Top 3 countries in EMEA
Exhibit 34: Liquid biopsy market in APAC – Market size and forecast 2017-2022 ($ mn)
Exhibit 35: Liquid biopsy market in APAC – Year-over-year growth 2018-2022 (%)
Exhibit 36: Top 3 countries in APAC
Exhibit 37: Market opportunity
Exhibit 38: Vendor landscape
Exhibit 39: Landscape disruption
Exhibit 40: Vendors covered
Exhibit 41: Vendor classification
Exhibit 42: Market positioning of vendors
Exhibit 43: BIOCEPT – Overview
Exhibit 44: BIOCEPT – Business segments
Exhibit 45: BIOCEPT – Organizational developments
Exhibit 46: BIOCEPT – Geographic focus
Exhibit 47: BIOCEPT – Key offerings
Exhibit 48: BIOCEPT – Key customers
Exhibit 49: Exosome Diagnostics – Overview
Exhibit 50: Exosome Diagnostics – Business segments
Exhibit 51: Exosome Diagnostics – Organizational developments
Exhibit 52: Exosome Diagnostics – Geographic focus
Exhibit 53: Exosome Diagnostics – Key offerings
Exhibit 54: Exosome Diagnostics – Key customers
Exhibit 55: F. Hoffmann-La Roche – Overview
Exhibit 56: F. Hoffmann-La Roche – Business segments
Exhibit 57: F. Hoffmann-La Roche – Organizational developments
Exhibit 58: F. Hoffmann-La Roche – Geographic focus
Exhibit 59: F. Hoffmann-La Roche – Segment focus
Exhibit 60: F. Hoffmann-La Roche – Key offerings
Exhibit 61: F. Hoffmann-La Roche – Key customers
Exhibit 62: GUARDANT HEALTH – Overview
Exhibit 63: GUARDANT HEALTH – Business segments
Exhibit 64: GUARDANT HEALTH – Organizational developments
Exhibit 65: GUARDANT HEALTH – Geographic focus
Exhibit 66: GUARDANT HEALTH – Key offerings
Exhibit 67: GUARDANT HEALTH – Key customers
Exhibit 68: Myriad Genetics – Overview
Exhibit 69: Myriad Genetics – Business segments
Exhibit 70: Myriad Genetics – Organizational developments
Exhibit 71: Myriad Genetics – Geographic focus
Exhibit 72: Myriad Genetics – Segment focus
Exhibit 73: Myriad Genetics – Key offerings
Exhibit 74: Myriad Genetics – Key customers
Exhibit 75: QIAGEN – Overview
Exhibit 76: QIAGEN – Product categories
Exhibit 77: QIAGEN – Organizational developments
Exhibit 78: QIAGEN – Geographic focus
Exhibit 79: QIAGEN – Product category focus
Exhibit 80: QIAGEN – Key offerings
Exhibit 81: QIAGEN – Key customers
PART 02: SCOPE OF THE REPORT
PART 03: RESEARCH METHODOLOGY
PART 04: MARKET LANDSCAPE
‧ Market ecosystem
‧ Market characteristics
‧ Market segmentation analysis
PART 05: MARKET SIZING
‧ Market definition
‧ Market sizing 2017
‧ Market size and forecast 2017-2022
PART 06: FIVE FORCES ANALYSIS
‧ Bargaining power of buyers
‧ Bargaining power of suppliers
‧ Threat of new entrants
‧ Threat of substitutes
‧ Threat of rivalry
‧ Market condition
PART 07: MARKET SEGMENTATION BY TECHNOLOGY
‧ Segmentation by technology
‧ Comparison by technology
‧ CTC and ctDNA
‧ Exosome and RNA
‧ Market opportunity by technology
PART 08: CUSTOMER LANDSCAPE
PART 09: REGIONAL LANDSCAPE
‧ Geographical segmentation
‧ Regional comparison
‧ Liquid biopsy market in Americas
‧ Liquid biopsy market in EMEA
‧ Liquid biopsy market in APAC
‧ Market opportunity
PART 10: DECISION FRAMEWORK
PART 11: DRIVERS AND CHALLENGES
‧ Market drivers
‧ Market challenges
PART 12: MARKET TRENDS
‧ Increasing funding/investment for liquid biopsy
‧ Strategic partnerships and M&A
‧ Emerging applications of liquid biopsy
PART 13: VENDOR LANDSCAPE
‧ Overview
‧ Landscape disruption
PART 14: VENDOR ANALYSIS
‧ Vendors covered
‧ Vendor classification
‧ Market positioning of vendors
‧ BIOCEPT
‧ Exosome Diagnostics
‧ F. Hoffmann-La Roche
‧ GUARDANT HEALTH
‧ Myriad Genetics
‧ QIAGEN
PART 15: APPENDIX
‧ List of abbreviations
Exhibit 01: Global IVD market
Exhibit 02: Global IVD market segmentation
Exhibit 03: Market characteristics
Exhibit 04: Market segments
Exhibit 05: Market definition - Inclusions and exclusions checklist
Exhibit 06: Global liquid biopsy market size 2017
Exhibit 07: Validation techniques employed for market sizing 2017
Exhibit 08: Global liquid biopsy market – Market size and forecast 2017-2022 ($ mn)
Exhibit 09: Global liquid biopsy market – Year-over-year growth 2018-2022 (%)
Exhibit 10: Five forces analysis 2017
Exhibit 11: Five forces analysis 2022
Exhibit 12: Bargaining power of buyers
Exhibit 13: Bargaining power of suppliers
Exhibit 14: Threat of new entrants
Exhibit 15: Threat of substitutes
Exhibit 16: Threat of rivalry
Exhibit 17: Market condition - Five forces 2017
Exhibit 18: Global liquid biopsy market by technology – Market share 2017-2022 (%)
Exhibit 19: Global liquid biopsy market – Comparison by technology
Exhibit 20: Global CTC and ctDNA market – Market size and forecast 2017-2022 ($ mn)
Exhibit 21: Global CTC and ctDNA market – Year-over-year growth 2018-2022 (%)
Exhibit 22: Global exosome and RNA market – Market size and forecast 2017-2022 ($ mn)
Exhibit 23: Global exosome and RNA market – Year-over-year growth 2018-2022 (%)
Exhibit 24: Market opportunity by technology
Exhibit 25: Customer landscape
Exhibit 26: Global liquid biopsy market by geography 2017-2022 (%)
Exhibit 27: Regional comparison
Exhibit 28: Liquid biopsy market in Americas – Market size and forecast 2017-2022 ($ mn)
Exhibit 29: Liquid biopsy market in Americas – Year-over-year growth 2018-2022 (%)
Exhibit 30: Top 3 countries in Americas
Exhibit 31: Liquid biopsy market in EMEA – Market size and forecast 2017-2022 ($ mn)
Exhibit 32: Liquid biopsy market in EMEA – Year-over-year growth 2018-2022 (%)
Exhibit 33: Top 3 countries in EMEA
Exhibit 34: Liquid biopsy market in APAC – Market size and forecast 2017-2022 ($ mn)
Exhibit 35: Liquid biopsy market in APAC – Year-over-year growth 2018-2022 (%)
Exhibit 36: Top 3 countries in APAC
Exhibit 37: Market opportunity
Exhibit 38: Vendor landscape
Exhibit 39: Landscape disruption
Exhibit 40: Vendors covered
Exhibit 41: Vendor classification
Exhibit 42: Market positioning of vendors
Exhibit 43: BIOCEPT – Overview
Exhibit 44: BIOCEPT – Business segments
Exhibit 45: BIOCEPT – Organizational developments
Exhibit 46: BIOCEPT – Geographic focus
Exhibit 47: BIOCEPT – Key offerings
Exhibit 48: BIOCEPT – Key customers
Exhibit 49: Exosome Diagnostics – Overview
Exhibit 50: Exosome Diagnostics – Business segments
Exhibit 51: Exosome Diagnostics – Organizational developments
Exhibit 52: Exosome Diagnostics – Geographic focus
Exhibit 53: Exosome Diagnostics – Key offerings
Exhibit 54: Exosome Diagnostics – Key customers
Exhibit 55: F. Hoffmann-La Roche – Overview
Exhibit 56: F. Hoffmann-La Roche – Business segments
Exhibit 57: F. Hoffmann-La Roche – Organizational developments
Exhibit 58: F. Hoffmann-La Roche – Geographic focus
Exhibit 59: F. Hoffmann-La Roche – Segment focus
Exhibit 60: F. Hoffmann-La Roche – Key offerings
Exhibit 61: F. Hoffmann-La Roche – Key customers
Exhibit 62: GUARDANT HEALTH – Overview
Exhibit 63: GUARDANT HEALTH – Business segments
Exhibit 64: GUARDANT HEALTH – Organizational developments
Exhibit 65: GUARDANT HEALTH – Geographic focus
Exhibit 66: GUARDANT HEALTH – Key offerings
Exhibit 67: GUARDANT HEALTH – Key customers
Exhibit 68: Myriad Genetics – Overview
Exhibit 69: Myriad Genetics – Business segments
Exhibit 70: Myriad Genetics – Organizational developments
Exhibit 71: Myriad Genetics – Geographic focus
Exhibit 72: Myriad Genetics – Segment focus
Exhibit 73: Myriad Genetics – Key offerings
Exhibit 74: Myriad Genetics – Key customers
Exhibit 75: QIAGEN – Overview
Exhibit 76: QIAGEN – Product categories
Exhibit 77: QIAGEN – Organizational developments
Exhibit 78: QIAGEN – Geographic focus
Exhibit 79: QIAGEN – Product category focus
Exhibit 80: QIAGEN – Key offerings
Exhibit 81: QIAGEN – Key customers
